MATTAWAN, Mich. - Tuesday, October 15th 2013 [ME NewsWire]
(BUSINESS WIRE)-- MPI Research, the largest single-site preclinical/early clinical contract research organization (CRO) worldwide, is pleased to announce that D. Thomas “Tom” Oakley has been appointed President and Chief Operating Officer. Tom recently joined the company as Executive Vice President of Preclinical Operations.
Oakley is an eminent senior executive with over 30 years of domestic and international strategic and operational leadership experience in major contract research organizations, industrial and consumer product businesses, and the United States Army. He most recently was President and CEO of ChanTest Corporation, a privately held global CRO that specializes in safety pharmacology and drug discovery services.
Prior to ChanTest, Oakley was the President and CEO of Bridge Laboratories, a multinational CRO with operations in the United States and China. In addition to leading a turnaround at the Maryland division, he established the first Western-quality GLP preclinical facility in China. Over the duration of his career, he has held leadership positions with DTO Associates, the Sarah Cannon Research Institute, Covance, Air Liquide America Corporation, Neodata Services, Inc., Pepsico, Inc., Container Corporation of America, and the United States Army, from which he was honorably discharged with the rank of Captain.
Oakley is a cum laude graduate of Ripon College where he received a BA degree in economics. He holds an MBA in management, finance, and accounting from the JL Kellogg Graduate School of Management at Northwestern University.
According to MPI Research Chairman and CEO, William U. Parfet, “Tom Oakley has been a leader his entire career in both the private and public sectors. His proven strength in business process redesign, performance improvement, and strategic planning and implementation will serve MPI Research well as we scale our operations and expand our presence globally. Our company will benefit from his industry knowledge, financial expertise, and business prowess, and we are excited about Tom’s expanded role on our leadership team.”
Oakley will report directly to Mr. Parfet. Please join us in congratulating Tom on his new responsibilities at MPI Research!
About MPI Research
MPI Research, with global headquarters in Mattawan, Michigan, provides safety evaluation, discovery, bioanalytical, and analytical services, and early clinical services and solutions to the biopharmaceutical, medical device, animal health, and chemical industries. Scientific knowledge and experience, responsiveness, integrity, trust, teamwork, and dedication to strong and enduring Sponsor relationships are the defining attributes that characterize MPI Research as a high-performance, high-quality organization that is committed to bringing safer and more effective products to the world. Learn more about how we can exceed your expectations at www.mpiresearch.com.
Contacts
MPI Research
Joan Manners, +1-269-668-3336
joan.manners@mpiresearch.com
Permalink: http://www.me-newswire.net/news/8832/en
(BUSINESS WIRE)-- MPI Research, the largest single-site preclinical/early clinical contract research organization (CRO) worldwide, is pleased to announce that D. Thomas “Tom” Oakley has been appointed President and Chief Operating Officer. Tom recently joined the company as Executive Vice President of Preclinical Operations.
Oakley is an eminent senior executive with over 30 years of domestic and international strategic and operational leadership experience in major contract research organizations, industrial and consumer product businesses, and the United States Army. He most recently was President and CEO of ChanTest Corporation, a privately held global CRO that specializes in safety pharmacology and drug discovery services.
Prior to ChanTest, Oakley was the President and CEO of Bridge Laboratories, a multinational CRO with operations in the United States and China. In addition to leading a turnaround at the Maryland division, he established the first Western-quality GLP preclinical facility in China. Over the duration of his career, he has held leadership positions with DTO Associates, the Sarah Cannon Research Institute, Covance, Air Liquide America Corporation, Neodata Services, Inc., Pepsico, Inc., Container Corporation of America, and the United States Army, from which he was honorably discharged with the rank of Captain.
Oakley is a cum laude graduate of Ripon College where he received a BA degree in economics. He holds an MBA in management, finance, and accounting from the JL Kellogg Graduate School of Management at Northwestern University.
According to MPI Research Chairman and CEO, William U. Parfet, “Tom Oakley has been a leader his entire career in both the private and public sectors. His proven strength in business process redesign, performance improvement, and strategic planning and implementation will serve MPI Research well as we scale our operations and expand our presence globally. Our company will benefit from his industry knowledge, financial expertise, and business prowess, and we are excited about Tom’s expanded role on our leadership team.”
Oakley will report directly to Mr. Parfet. Please join us in congratulating Tom on his new responsibilities at MPI Research!
About MPI Research
MPI Research, with global headquarters in Mattawan, Michigan, provides safety evaluation, discovery, bioanalytical, and analytical services, and early clinical services and solutions to the biopharmaceutical, medical device, animal health, and chemical industries. Scientific knowledge and experience, responsiveness, integrity, trust, teamwork, and dedication to strong and enduring Sponsor relationships are the defining attributes that characterize MPI Research as a high-performance, high-quality organization that is committed to bringing safer and more effective products to the world. Learn more about how we can exceed your expectations at www.mpiresearch.com.
Contacts
MPI Research
Joan Manners, +1-269-668-3336
joan.manners@mpiresearch.com
Permalink: http://www.me-newswire.net/news/8832/en
No comments:
Post a Comment